The Changing Face of Clinical Trials in Psoriatic Arthritis

Abstract

Purpose of the review We will address current treatment and unmet needs in psoriatic arthritis (PsA), examine existing randomized controlled trials (RCTs), and consider options for new trial designs and challenges in their implementation. Recent Findings While therapeutic options for PsA have rapidly increased, there continues to be a need for clinical trials to test new therapies and establish optimal treatment strategies in order to improve the care for patients with PsA. In addition, more data is needed on how to select the best therapy for a given patient in clinical practice. Consideration of alternative outcome measures is also needed. Summary Despite the rapid expansion in the number of therapy options available, there is still much to be learned about how to treat the individual patient with PsA.

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments

“…Twelve articles fulfilling our criteria were finally selected (table 1) (two for etanercept, two for infliximab, one for adalimumab, one for golimumab, one for certolizumab pegol, two for ustekinumab, two for secukinumab and one for apremilast). Our final list was compared with an overview of psoriatic arthritis clinical trials as published by Ogdie and Coates 5. Three periods for novel treatments were defined.…”

Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

“…Oligoarticular psoriatic arthritis (PsA), defined as <5 involved joints (1,2), affects ≈50% of patients with PsA (3). Typical randomized controlled trials have not focused on this population, and, on average, patients enrolled have swollen and tender joint counts of 12 and 21, respectively (4). Despite the high prevalence of oligoarticular PsA, data are lacking in this population, and recommendations for management remain largely unaddressed (4)(5)(6).…”

SEAM‐PsA: Seems Like Methotrexate Works in Psoriatic Arthritis?

“…SEAM‐PsA greatly underscores the need for more head‐to‐head trials in PsA to inform treatment guidelines, comparative effectiveness, and cost research. Of equal importance are more comparative effectiveness studies in the real world, to appropriately inform clinical practice . SEAM‐PsA enrolled patients who were typical of trial patients, but who represented fewer than one‐half the patients in clinical practice .…”